The onshore RMB against the US dollar officially closed at 7.2590 at 16:30 Beijing time, down 97 points from the official closing price of the previous trading day and down 99 points from the closing price of the previous day and night.Jiayi Co., Ltd.: It plans to increase capital by 28 million US dollars to set up Vietnam Sun Company. Jiayi Co., Ltd. announced that the company plans to increase capital by 28 million US dollars to its wholly-owned subsidiary Jiayi Singapore with its own funds for the establishment of wholly-owned Sun Company Jiayi Drinking Water Co., Ltd. in Vietnam. This investment aims at expanding overseas production bases, enhancing supply chain flexibility, enhancing core competitiveness and accelerating business internationalization.SpaceX is valued at about $350 billion due to internal stock sales. According to an email sent to employees seen by the media, SpaceX and its investors have agreed to acquire the company's common stock of up to $1.25 billion at a price of $185 per share. This transaction values the rocket and satellite manufacturer owned by elon musk at about $350 billion. The memo said that the price of $185 per share was much higher than the valuation of $112 less than three months ago. The memorandum was further confirmed by insiders. According to the memo, only SpaceX offered to buy up to $500 million in common stock.
Bank of America: Resume the coverage of Lilly and give it a "buy" rating with a target price of $997.In November, the scale of wealth management exceeded expectations, and the scale of 14 wealth management companies increased by over 420 billion yuan. In November, the product scale of wealth management companies ushered in a general increase. According to the obtained data, in November, there were 6 state-owned wealth management companies and 8 joint-stock wealth management companies (CMB, Xingyin, Everbright, Xinyin, Ping 'an, Huaxia, Puyin and Minsheng), totaling 14 wealth management companies, with a survival scale of nearly 22.6 trillion yuan, an increase of more than 420 billion yuan compared with October, and the growth rate was slightly lower than the impact of capital backflow in October. (21st century business herald)The detailed rules for the examination of egg products production license clearly require the transportation temperature of liquid eggs and frozen egg products, and the General Administration of Market Supervision publicly solicited opinions on the detailed rules for the examination of egg products production license (draft for comments). The deadline for feedback is January 11, 2025. The "Draft for Comment" clarifies that egg product manufacturers should formulate salmonella monitoring plans and implement effective monitoring in combination with production technology and product characteristics; Self-inspection enterprises should have inspection rooms and inspection capabilities suitable for the inspected items, and verify the inspection capabilities of the inspected items at least once a year. The use of rapid detection methods and equipment should be compared or verified with the inspection methods specified by national standards on a regular basis to ensure the accuracy of the test results. At the same time, the transportation temperature of liquid egg products should be controlled at 0-4℃, and the transportation temperature of frozen egg products should be controlled below -13℃.
Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Xie Yunliang, macro chief analyst of Cinda Securities, said that historically, the establishment of a "moderately loose" policy orientation needs to meet two major conditions, namely, the domestic pressure to stabilize prices is high and the foreign Federal Reserve is in a loose cycle. At present, it is judged that both situations may exist next year.Morgan Asset Management: In 2025, there are sufficient reasons to continue to over-allocate US stocks. Sylvia Sheng, global multi-asset strategist of Morgan Asset Management, said that there are sufficient reasons to continue to over-allocate US stocks and increase exposure to small and medium-sized stocks. She pointed out that although the valuation may look high, it is expected that the profit growth of S&P 500 companies will continue. Sheng wrote that it is estimated that in 2025, the contribution of the six giants in the S&P 500 index to the profit growth of the other 494 stocks will be the same, and the profit growth of these six giants is expected to slow down from 40% in 2024 to 22%. In the international market, Morgan Asset Management continues to over-allocate Japanese stocks, and its quantitative model shows that the yield of Japanese stocks is attractive and the bottom-up profitability is strong.
Strategy guide
Strategy guide